A Case Report published recently in Wiley Online, hypothesizing that the SARS‐CoV‐2 infection could have triggered an anti-tumor immune response. The case was a 61‐year‐old man referred to the hematology department in a UK hospital, with progressive lymphadenopathy and weight loss. He was receiving hemodialysis for end‐stage renal failure secondary to IgA nephropathy. He had been off immunosuppressive therapy for three years after a failed renal transplant. Needle‐core biopsy showed Epstein–Barr virus (EBV)‐positive classical Hodgkin Shortly after diagnosis, he suffered from breathlessness and wheeze and was diagnosed with PCR‐positive SARS‐CoV‐2 pneumonia. He was then discharged, after 11 days of supportive treatment, to convalesce at home. However, no corticosteroid or immunochemotherapy was administered.

Four months later, it was found that the palpable lymphadenopathy had reduced, as well as the viral EBV PCR.

The author concluded that the SARS‐CoV‐2 infection could have triggered an anti-tumor immune response, as has been described with other infections in the context of high‐grade non‐Hodgkin lymphoma.

Source:
1. Wiley Online. Challenor, S. (2021). SARS‐CoV‐2‐induced remission of Hodgkin lymphoma. https://onlinelibrary.wiley.com/doi/10.1111/bjh.17116. Accessed 12 Jan 2021.